University of California, Los Angeles

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1919-05-23

Employees: 10K

Market Cap: -

Website: http://www.ucla.edu

Clinical Trials

A Six-month Study to Compare Outcome Differences and Visceral Response ... Irritable Bowel Syndrome

Not Applicable

Completed

Conditions: Irritable Bowel Syndrome

Interventions: Behavioral: IBS Stress Management
Behavioral: IBS Educational Training
Behavioral: IBS Symptom Management

First Posted Date: 2006-08-25

Last Posted Date: 2016-11-28

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 163

Registration Number: NCT00368771

Understanding the Genetic Basis of Familial Combined Hyperlipidemia in Mexican Individuals

Completed

Conditions: Hyperlipidemia, Familial Combined
Coronary Disease

First Posted Date: 2006-08-17

Last Posted Date: 2012-01-12

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 998

Registration Number: NCT00365235

Locations: 🇲🇽
Instituto Nacional De Ciencias Medicas y Nutricion, Mexico City, Mexico

Effects of Atorvastatin on Disease Activity and HDL Cholesterol Function in Patients With Rheumatoid Arthritis

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Atorvastatin

First Posted Date: 2006-07-26

Last Posted Date: 2012-06-22

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 20

Registration Number: NCT00356473

Amyloid Plaque and Tangle Imaging in Aging and Dementia

Completed

Conditions: Alzheimer's Disease
Memory Disorders

First Posted Date: 2006-07-24

Last Posted Date: 2020-05-06

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 170

Registration Number: NCT00355498

Locations: 🇺🇸
Jane & Terry Semel Institute for Neuroscience & Human Behavior, Los Angeles, California, United States

Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)

Phase 1

Completed

Conditions: Neurofibromatosis 1

Interventions: Drug: placebo pill
Drug: Lovastatin

First Posted Date: 2006-07-14

Last Posted Date: 2016-11-22

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 44

Registration Number: NCT00352599

Locations: 🇺🇸
Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Behavioral: Cognitive remediation training (CT)
Behavioral: Healthy behavior training (HBT)
Drug: Risperidone, administered via injection (RLAI)
Drug: Risperidone, administered orally (Oral Ris)

First Posted Date: 2006-06-02

Last Posted Date: 2020-03-26

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 92

Registration Number: NCT00333177

Locations: 🇺🇸
Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, California, United States

Effectiveness of Family-Focused Treatment Plus Pharmacotherapy for Bipolar Disorder in Adolescents

Phase 3

Completed

Conditions: Bipolar Disorder

Interventions: Behavioral: Family-Focused Treatment Plus Pharmacotherapy
Behavioral: Enhanced Care Plus Pharmacotherapy

First Posted Date: 2006-06-01

Last Posted Date: 2014-05-20

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 145

Registration Number: NCT00332098

Locations: 🇺🇸
University of Colorado, Dept. of Psychology, Boulder, Colorado, United States
🇺🇸
Cincinnati Children's Hospital Medical Center/MLC 3014, Cincinnati, Ohio, United States
🇺🇸
University of Pittsburgh Medical Center Western Psychiatric Institute, Pittsburgh, Pennsylvania, United States

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: Risperidone in Long-Acting Injectable Form (Consta)
Drug: Oral Risperidone

First Posted Date: 2006-05-29

Last Posted Date: 2023-03-01

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 126

Registration Number: NCT00330551

Locations: 🇺🇸
Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, California, United States

Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)

Not Applicable

Completed

Conditions: Dementia

Interventions: Procedure: FDG-PET brain scan

First Posted Date: 2006-05-25

Last Posted Date: 2017-05-02

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 710

Registration Number: NCT00329706

Locations: 🇺🇸
Santa Monica-UCLA Medical Center, Santa Monica, California, United States
🇺🇸
University of Buffalo, Buffalo, New York, United States
🇺🇸
UCLA Medical Center, Los Angeles, California, United States

and more 6 locations

Starting Treatment With Agonist Replacement Therapies (START)

Phase 4

Completed

Conditions: Opiate-related Disorders

Interventions: Drug: Buprenorphine/naloxone
Drug: Methadone

First Posted Date: 2006-04-18

Last Posted Date: 2017-01-06

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 1269

Registration Number: NCT00315341

Locations: 🇺🇸
Matrix Institute, Los Angeles, California, United States
🇺🇸
BAART; Turk Street Clinic, San Francisco, California, United States
🇺🇸
CODA-Research, Portland, Oregon, United States

and more 6 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy